Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Keywords

Brief description/objective

Treatment patterns and Outcomes across the disease Continuum in
patients with CAD and/or PAD

The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg [twice
a day (BID)] plus low-dose ASA (75-100 mg) [once a day
(OD)] for the prevention of atherothrombotic events in adult
patients at high risk of ischemic events, and to describe the
outcomes under this combination across the broad range of
patient risk profiles encountered in routine clinical practice